.. Cetuximab is administered weekly with a loading dose of 400 mg/m2 iv over 2 hours during the first week followed by 250 mg/m2 iv over 1 hour weekly. The mean half-life is approximately 112 hours (range, 63-230 hours) (17). A small Danish study looked at giving cetuximab at 500 mg/m2 iv every other week, as

pharmacokinetic studies have not revealed much differences Inhibitors,research,lifescience,medical with the two schedules, and found efficacy and safety to be similar compared to their own historical controls with weekly administration (18). The NCCN guidelines allow for using both the weekly and biweekly schedules of cetuximab as published (19). In contrast, panitumumab Inhibitors,research,lifescience,medical is a fully humanized recombinant monoclonal IgG-2 kappa antibody which demonstrated good single-agent activity in EGFR expressing tumors in mouse models and is expected to exhibit minimal immunogenicity and therefore allow for repeated administrations without the development of antibodies (20). It was approved by the FDA as a single agent in September 2006. As ADCC is dependent upon an antibody’s subclass it is unlikely that panitumumab exerts much ADCC as it is bound to IgG-2 so its effects are mainly through blocking the receptor from binding agonists and through receptor internalization (see Figure 1). Panitumumab is approved as single agent Inhibitors,research,lifescience,medical therapy with a dosing of 6 mg/kg iv every 2 weeks

and has a half-life of approximately 7.5 days (range, 3.6-10.9 days) (21). Both cetuximab and panitumumab are cleared by receptor internalization and do not require any dose reductions for renal or hepatic impairment. Biomarkers The mutational status of KRAS, Inhibitors,research,lifescience,medical a Kirsten ras oncogene homolog from the ras gene family located on chromosome 12p12.1, was shown to predict responses to EGFR-targeted

therapy in a study published in 2006 (22). Lievre et al. investigated 30 patients treated with cetuximab, 11 of whom had a response, for mutations in KRAS, BRAF and PIK3CA by direct sequencing as well as EGFR copy number by chromogenic Inhibitors,research,lifescience,medical in situ hybridization. They found no KRAS mutations in the 11 patients who PD184352 (CI-1040) had a response while 13 of the 19 nonresponders were found to have mutations in KRAS. None of the tumors had BRAF mutations and only 2 (7%) had exon 9 PIK3CA mutations. EGFR copy number was increased in only 3 patients but was associated with a response (P=0.004) (22). Most commonly mutations occur in codons 12, 13 or 61 in exon 2. In a large population-based study, 37% of KRAS mutations occurred within codons 12 and 13, with 6.6% occurring in codons 8, 9, 10, 15, 16, 19, 20 and 25 (23). After Lievre’s publication in 2006, multiple investigators looked at their CCI-779 research buy clinical trial results with respect to KRAS mutational status and confirmed the predictive value of KRAS testing (24-31).